{
    "clinical_study": {
        "@rank": "85532", 
        "arm_group": [
            {
                "arm_group_label": "Carvedilol", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate if carvedilol can prevent the cardiotoxicity after\n      chemotherapy in breast cancer."
        }, 
        "brief_title": "Effect of Beta-Blockers in Preventing Chemotherapy - Induced Cardiotoxicity", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Heart Failure", 
            "Cardiotoxicity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Heart Failure"
            ]
        }, 
        "detailed_description": {
            "textblock": "Dilated cardiomyopathy secondary to chemotherapy accounts for approximately 1% of all\n      dilated cardiomyopathies.\n\n      Initial studies showed beneficial effect of the use of carvedilol for the prevention of\n      chemotherapy-induced cardiomyopathy. This study has the objective to evaluate the\n      effectiveness of carvedilol for the prevention of chemotherapy-induced cardiomyopathy. Will\n      be selected 200 patients referred for chemotherapy that includes  anthracyclines for breast\n      cancer.These patients will be randomized to carvedilol or placebo and will have periodic\n      assessment of cardiac function with echocardiography and biomarkers until complete\n      chemotherapy and 24 months later."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients diagnosed with breast cancer, with an indication of chemotherapy that includes\n        anthracycline.\n\n        Exclusion Criteria:\n\n        Failure analysis of ventricular function; History of chemotherapy or radiotherapy;\n        Previous symptoms of heart failure; Presence of cardiomyopathy; Presence of Coronary\n        Artery Disease; Aortic valve disease or moderate to severe mitral regurgitation;\n        Contraindication to the use of \u03b2-blocker; Use of inhibitors of angiotensin converting\n        enzyme, angiotensin receptor blockers or \u03b2-blockers.\n\n        Patients with HER 2 expression"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724450", 
            "org_study_id": "Cardiotox Incor"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carvedilol", 
                "description": "50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day", 
                "intervention_name": "Carvedilol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Placebo similar to the carvedilol up titration but wit no active drug.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic beta-Antagonists", 
                "Carvedilol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Heart Failure", 
            "Cardiotoxicity", 
            "Biomarkers"
        ], 
        "lastchanged_date": "November 6, 2012", 
        "location": {
            "contact": {
                "email": "edimar.bocchi@incor.usp.br", 
                "last_name": "Edimar Alcides Bocchi, PHD", 
                "phone": "+551126615419"
            }, 
            "contact_backup": {
                "email": "silvia.ayub@incor.usp.br", 
                "last_name": "Silvia Moreira Ayub-Ferreira, PHD", 
                "phone": "+551126615419"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "zip": "05403-000"
                }, 
                "name": "Heart Institute University of Sao Paulo"
            }, 
            "investigator": [
                {
                    "last_name": "Monica Samuel Avila, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Solange Moraes Sanches, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double Blind Study on the Effect of Beta-Blockers in Preventing Chemotherapy - Induced Cardiotoxicity.", 
        "overall_contact": {
            "email": "edimar.bocchi@incor.usp.br", 
            "last_name": "Edimar Alcides Bocchi, PHD", 
            "phone": "+551126615419"
        }, 
        "overall_contact_backup": {
            "email": "silvia.ayub@incor.usp.br", 
            "last_name": "Silvia Moreira Ayub-Ferreira, PHD", 
            "phone": "+551126615419"
        }, 
        "overall_official": {
            "affiliation": "Heart Institute of University of Sao Paulo", 
            "last_name": "Edimar Alcides Bocchi, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10% drop in ejection fraction of left ventricle.", 
            "safety_issue": "Yes", 
            "time_frame": "96 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724450"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Sao Paulo", 
            "investigator_full_name": "Edimar Alcides Bocchi", 
            "investigator_title": "phd", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Prevention of myocardial injury measured by the levels of biomarkers (ultrasensitive troponin, BNP and miRNA-208) Effect of carvedilol in the prevention of diastolic dysfunction.", 
            "safety_issue": "Yes", 
            "time_frame": "96 weeks"
        }, 
        "source": "University of Sao Paulo", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hospital A.C. Camargo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Sao Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}